Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Search Results

44 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Structural insights into the role and targeting of EGFRvIII.
Bagchi A, Stayrook SE, Xenaki KT, Starbird CA, Doulkeridou S, El Khoulati R, Roovers RC, Schmitz KR, van Bergen En Henegouwen PMP, Ferguson KM. Bagchi A, et al. Among authors: roovers rc. Structure. 2024 Jun 19:S0969-2126(24)00195-3. doi: 10.1016/j.str.2024.05.018. Online ahead of print. Structure. 2024. PMID: 38908376
A bispecific T cell engager recruits both type 1 NKT and Vγ9Vδ2-T cells for the treatment of CD1d-expressing hematological malignancies.
Lameris R, Ruben JM, Iglesias-Guimarais V, de Jong M, Veth M, van de Bovenkamp FS, de Weerdt I, Kater AP, Zweegman S, Horbach S, Riedl T, Winograd B, Roovers RC, Adang AEP, de Gruijl TD, Parren PWHI, van der Vliet HJ. Lameris R, et al. Among authors: roovers rc. Cell Rep Med. 2023 Mar 21;4(3):100961. doi: 10.1016/j.xcrm.2023.100961. Epub 2023 Mar 2. Cell Rep Med. 2023. PMID: 36868236 Free PMC article.
A Bispecific γδ T-cell Engager Targeting EGFR Activates a Potent Vγ9Vδ2 T cell-Mediated Immune Response against EGFR-Expressing Tumors.
King LA, Toffoli EC, Veth M, Iglesias-Guimarais V, Slot MC, Amsen D, van de Ven R, Derks S, Fransen MF, Tuynman JB, Riedl T, Roovers RC, Adang AEP, Ruben JM, Parren PWHI, de Gruijl TD, van der Vliet HJ. King LA, et al. Among authors: roovers rc. Cancer Immunol Res. 2023 Sep 1;11(9):1237-1252. doi: 10.1158/2326-6066.CIR-23-0189. Cancer Immunol Res. 2023. PMID: 37368791
Functional patient-derived organoid screenings identify MCLA-158 as a therapeutic EGFR × LGR5 bispecific antibody with efficacy in epithelial tumors.
Herpers B, Eppink B, James MI, Cortina C, Cañellas-Socias A, Boj SF, Hernando-Momblona X, Glodzik D, Roovers RC, van de Wetering M, Bartelink-Clements C, Zondag-van der Zande V, Mateos JG, Yan K, Salinaro L, Basmeleh A, Fatrai S, Maussang D, Lammerts van Bueren JJ, Chicote I, Serna G, Cabellos L, Ramírez L, Nuciforo P, Salazar R, Santos C, Villanueva A, Stephan-Otto Attolini C, Sancho E, Palmer HG, Tabernero J, Stratton MR, de Kruif J, Logtenberg T, Clevers H, Price LS, Vries RGJ, Batlle E, Throsby M. Herpers B, et al. Among authors: roovers rc. Nat Cancer. 2022 Apr;3(4):418-436. doi: 10.1038/s43018-022-00359-0. Epub 2022 Apr 25. Nat Cancer. 2022. PMID: 35469014 Free article.
A Bispecific Antibody Antagonizes Prosurvival CD40 Signaling and Promotes Vγ9Vδ2 T cell-Mediated Antitumor Responses in Human B-cell Malignancies.
de Weerdt I, Lameris R, Scheffer GL, Vree J, de Boer R, Stam AG, van de Ven R, Levin MD, Pals ST, Roovers RC, Parren PWHI, de Gruijl TD, Kater AP, van der Vliet HJ. de Weerdt I, et al. Among authors: roovers rc. Cancer Immunol Res. 2021 Jan;9(1):50-61. doi: 10.1158/2326-6066.CIR-20-0138. Epub 2020 Nov 11. Cancer Immunol Res. 2021. PMID: 33177109
MCLA-117, a CLEC12AxCD3 bispecific antibody targeting a leukaemic stem cell antigen, induces T cell-mediated AML blast lysis.
van Loo PF, Hangalapura BN, Thordardottir S, Gibbins JD, Veninga H, Hendriks LJA, Kramer A, Roovers RC, Leenders M, de Kruif J, Doornbos RP, Sirulnik A, Throsby M, Logtenberg T, Dolstra H, Bakker ABH. van Loo PF, et al. Among authors: roovers rc. Expert Opin Biol Ther. 2019 Jul;19(7):721-733. doi: 10.1080/14712598.2019.1623200. Expert Opin Biol Ther. 2019. PMID: 31286786
The architecture of EGFR's basal complexes reveals autoinhibition mechanisms in dimers and oligomers.
Zanetti-Domingues LC, Korovesis D, Needham SR, Tynan CJ, Sagawa S, Roberts SK, Kuzmanic A, Ortiz-Zapater E, Jain P, Roovers RC, Lajevardipour A, van Bergen En Henegouwen PMP, Santis G, Clayton AHA, Clarke DT, Gervasio FL, Shan Y, Shaw DE, Rolfe DJ, Parker PJ, Martin-Fernandez ML. Zanetti-Domingues LC, et al. Among authors: roovers rc. Nat Commun. 2018 Oct 18;9(1):4325. doi: 10.1038/s41467-018-06632-0. Nat Commun. 2018. PMID: 30337523 Free PMC article.
A bispecific nanobody approach to leverage the potent and widely applicable tumor cytolytic capacity of Vγ9Vδ2-T cells.
de Bruin RCG, Veluchamy JP, Lougheed SM, Schneiders FL, Lopez-Lastra S, Lameris R, Stam AG, Sebestyen Z, Kuball J, Molthoff CFM, Hooijberg E, Roovers RC, Santo JPD, van Bergen En Henegouwen PMP, Verheul HMW, de Gruijl TD, van der Vliet HJ. de Bruin RCG, et al. Among authors: roovers rc. Oncoimmunology. 2017 Oct 20;7(1):e1375641. doi: 10.1080/2162402X.2017.1375641. eCollection 2017. Oncoimmunology. 2017. PMID: 29296532 Free PMC article.
44 results